Aether Industries Ltd

- No explicit mention of any current or future fundraising through debt or equity is provided in the transcript. - The company discusses significant ongoing and planned capital expenditures (capex) around INR 500 crores for Site 3++ and Site 5, with capitalization expected in the near term. - There is an emphasis on managing working capital efficiently, which currently stands around 160 days. - No guidance or comments were made about raising additional funds through debt or equity during the call. - The management seems focused on organic growth funded through operations and capex planning rather than external fundraising at this stage.

- Capex done so far in 9 months: Approximately INR 500 crores for Site 3++ and Site 5 (Panoli). - Full year capex expected: Approximately INR 450-500 crores. - Site 3++ capex: Approximately INR 260 crores. - Phase 1 (2 blocks) of Site 5 expected to be ready and capitalized within the year. - Future capacity additions: Plan to expand Converge polyol capacity to 2 KTA (2,000 tonnes per annum). - Monitoring inbound inquiries to fast-track expansions if necessary. - Strategy allows for capitalizing on the current pipeline and scaling up assets as required.

- Baker Hughes business is trending upwards with 20% quarter-on-quarter growth in Q3 FY26, expected to continue increasing as more sites and products are added. - Large scale manufacturing (LSM) volume growth is over 10% quarter-on-quarter and 25% year-on-year; additional new products added in Site 5 targeted at pharma and agro sectors. - Converge polyol sales continue to increase, with good demand expected for FY26 and FY27; target to expand capacity to 2 KTA (~2,000 tonnes) in coming years. - New marquee clients added in LSM segment, with commercial production soon from Site 5 products. - Otsuka Chemical contract expected to deliver INR 35-40 crores sales in FY26. - Semiconductor electronic chemicals validation batches dispatched, with potential growth from these advanced products. - Overall, management is optimistic of sustained volume and revenue growth driven by expanding product pipelines, strategic partnerships, and capacity ramp-ups over the next 1-3 years.

- Revenue from Baker Hughes is trending upwards with 20% quarter-on-quarter growth in Q3 FY26, expected to continue growing through FY27 as product offerings and site coverage expand. - Large-scale manufacturing volume growth is over 25% year-on-year and 10% quarter-on-quarter, indicating strong demand and volume ramp-up. - EBITDA margins are expected around 29-30%, considering a conservative estimate without one-time income. - CRAMS segment has high margins of 60%-65%, CEM margins between 27%-30%, and LSM margins between 21%-23%, shaping overall profitability. - CEM and CRAMS expected to contribute 70% of revenues in medium term, increasing higher-margin business share. - New products and capacity expansions (Site 3++ and Site 5) poised to ramp up, with utilization targets of 45%-50% (Site 3++) and 35%-40% (Site 5) in FY27. - Management refrains from explicit forward guidance but indicates a positive and growing trend in revenues and margins.

- The company currently services Baker Hughes with 8 products in commercial production (Site 4) generating a run rate of INR 60 crores this quarter. - There are an additional 7 to 8 products in the pipeline under research and scale-up stages. - Management refrains from commenting on the potential market size or forward-looking orderbook details. - Contract manufacturing (CRAMS) clients may pay advances or require Aether to invest upfront on strategic long-term projects. - Contracts generally span 5 to 10 years and auto-renew, with pricing negotiated annually. - The company aims to grow its strategic partnerships, especially with Baker Hughes, across a broader portfolio of products over the next decades. - No explicit total order book or pending order quantum was disclosed in the call transcript.